Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Buttari

Showing results (41-50 of 131) with videos related to

Pageof 14
Sort By:
CNS Neuroscience & Therapeutics|May 20, 2014
Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroidsSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Journal of Neuroinflammation|February 20, 2014
Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosisSilvia Rossi, Valeria Studer, Caterina Motta, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2012
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivationSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Neurology|February 24, 2017
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PMLDoriana Landi, Nicola De Rossi, Sara Zagaglia, et al.
Frontiers in Aging Neuroscience|August 24, 2018
Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive FunctionsAlessandra Musella, Antonietta Gentile, Francesca Romana Rizzo, et al.
Neuromolecular Medicine|March 28, 2014
Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosisFrancesco Mori, Carolina G Nicoletti, Silvia Rossi, et al.
Human Molecular Genetics|April 25, 2018
Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's diseaseAlba Di Pardo, Salvatore Castaldo, Enrico Amico, et al.
BMC Neurology|July 1, 2020
A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onsetRosa Campopiano, Rosangela Ferese, Stefania Zampatti, et al.
Journal of Clinical Medicine|August 28, 2025
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic NeuropathyLucilla Barbano, Lucia Ziccardi, Carmen Dell'Aquila, et al.
Parkinsonism & Related Disorders|March 3, 2024
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammationMario Stampanoni Bassi, Luana Gilio, Giovanni Galifi, et al.
Pageof 14

Showing results (41-50 of 131) with videos related to

Sort By:
Pageof 14
CNS Neuroscience & Therapeutics|May 20, 2014
Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroidsSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Journal of Neuroinflammation|February 20, 2014
Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosisSilvia Rossi, Valeria Studer, Caterina Motta, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 12, 2012
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivationSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Neurology|February 24, 2017
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PMLDoriana Landi, Nicola De Rossi, Sara Zagaglia, et al.
Frontiers in Aging Neuroscience|August 24, 2018
Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive FunctionsAlessandra Musella, Antonietta Gentile, Francesca Romana Rizzo, et al.
Neuromolecular Medicine|March 28, 2014
Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosisFrancesco Mori, Carolina G Nicoletti, Silvia Rossi, et al.
Human Molecular Genetics|April 25, 2018
Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's diseaseAlba Di Pardo, Salvatore Castaldo, Enrico Amico, et al.
BMC Neurology|July 1, 2020
A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onsetRosa Campopiano, Rosangela Ferese, Stefania Zampatti, et al.
Journal of Clinical Medicine|August 28, 2025
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic NeuropathyLucilla Barbano, Lucia Ziccardi, Carmen Dell'Aquila, et al.
Parkinsonism & Related Disorders|March 3, 2024
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammationMario Stampanoni Bassi, Luana Gilio, Giovanni Galifi, et al.
Pageof 14